[ad_1] While there has been plenty of buzz about how successful patients have been in losing weight while taking a new class of obesity medications, there is a growing realization that when people stop taking these pricey drugs, the pounds can creep back on. There was a frank discussion of this on Eli Lilly’s first-quarter…
[ad_1] Carl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016. David A. Grogan | CNBC Carl Icahn on Friday called Illumina’s first-quarter results “very disappointing” and slammed the DNA sequencing company’s new plans to cut costs. The activist investor, who owns a 1.4% stake in Illumina, is in a heated proxy…
[ad_1] Eli Lilly‘s first-quarter earnings missed expectations Thursday, but the pharmaceutical company raised its full-year guidance. Before the earnings release, the company also reported positive data on its weight loss drug tirzepatide. related investing news Eli Lilly’s stock closed nearly 4% higher at $390.35 a share. The company’s revenue fell 11% compared with the same…
[ad_1] Patients who took Eli Lilly‘s weight loss drug tirzepatide lost up to 34 pounds on average, or 16% of their body weight, the company said in clinical trial results released Thursday. Eli Lilly plans to complete its application for Food and Drug Administration approval of the drug in the coming weeks and expects regulatory…
[ad_1] In this photo illustration, packages of Mifepristone tablets are displayed at a family planning clinic on April 13, 2023 in Rockville, Maryland. Anna Moneymaker | Getty Images The abortion pill mifepristone is either banned or restricted to varying degrees in 27 states despite a Supreme Court decision that — for now — maintains Food…
[ad_1] Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on October 4, 2021. NurPhoto | NurPhoto | Getty Images Merck on Thursday reported first-quarter revenue that fell 9% from the same period a year ago largely due to a steep drop in…
[ad_1] Chiquita Brooks-LaSure testifies before the Senate Finance Committee during her nomination hearing to be administrator of the Centers for Medicare & Medicaid Services in Washington on Thursday, April 15, 2021. Caroline Brehman | CQ-Roll Call, Inc. | Getty Images Medicare will cover the new Alzheimer’s treatment Leqembi for all patients eligible under the medication’s…
[ad_1] A building on the campus at the world headquarters of Illumina is shown in San Diego, California, September 1, 2021. Mike Blake | Reuters Illumina on Tuesday unveiled plans to cut costs in a bid to improve the DNA sequencing company’s shrinking margins. The plans aim to reduce Illumina’s annualized run rate expenses by…
[ad_1] A health care worker prepares a dose of the JYNNEOS Monkeypox vaccine at a pop-up vaccination clinic in Los Angeles, California, on August 9, 2022. Patrick T. Fallon | AFP | Getty Images The maker of the mpox vaccine is looking at ways to dramatically scale up its production capacity to prepare for a…
[ad_1] A person skateboards past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images Biogen isn’t worried about competing with Eli Lilly as they both attempt to bring an Alzheimer’s drug to the market, Biogen’s CEO said Tuesday. “I think it will be good if there…
